



Our mission is to convene a multidisciplinary learning collaborative of Illinois Commission on Cancer accredited hospitals improving the safety and quality of care for cancer patients.



Improve patient outcomes by ensuring that Stage IB-IIIA resectable Non-Small Cell Lung Cancer (NSCLC) patients and 1L Stage IV NSCLC patients undergo molecular profiling, and the results are available to oncologists and patients prior to the selection and initiation of treatment.

WHY LUNG CANCER

- It is the leading cause of cancer-related mortality in the US, accounting for 221,200 new cases and 158,040 deaths annually (more than colon, breast, prostate and brain cancers combined).
- Recent advances in NSCLC have led to substantial changes in treatment paradigms, with the use of targeted therapies and the associated molecular testing recommended in widely accepted national best practice guidelines.
- Despite this, many lung cancer patients do not undergo molecular profiling to determine eligibility for targeted therapy prior to initiation of treatment.

ABOUT THE ILCC

The first-of-its-kind cancer collaborative. It facilitates a statewide network of five working groups focused on four high volume clinical areas: breast cancer, colorectal cancer, lung cancer, and prostate cancer, including one additional group focused on hospital and/or cancer center operations. We engage providers and institutions through cancer Quality Improvement (QI) projects that look to improve the following: adherence to well-accepted cancer care guidelines; variation reduction in cancer care statewide; and finally overall improvement of patient outcomes, by providing tailored support and resources to local cancer OI teams to address the difficulties of understanding and effectively improving processes to provide bestpractice cancer care.

Connect with us!

Let's grow this collaborative together



202-725-3279



info@ilcancer.org



www.ilcancer.org

